HCV Infection
57
1
3
39
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
12 trials with published results (21%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.3%
3 terminated out of 57 trials
92.9%
+6.4% vs benchmark
7%
4 trials in Phase 3/4
31%
12 of 39 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 39 completed trials
Clinical Trials (57)
"Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"
Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia
Hepatitis B and C Within the Chinese Community in Milan
The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an
Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV
APPROACH 2.0: HIV, HCV and Syphilis Testing Through Pharmacies
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)
Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)
PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
A Community-based Intervention Among Active Drug Users in Montpellier
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)
Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid
Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection
Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment